DOCSLIB.ORG

49Th Annual ESDR Meeting September 18–21, 2019 Bordeaux, France

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
49Th Annual ESDR Meeting September 18–21, 2019 Bordeaux, France Volume 139, Number 9S, Supplement 2, September 2019 www.jidonline.org Supplement to the Journal of Investigative Dermatology 49th Annual ESDR Meeting September 18–21, 2019 Bordeaux, France JJID_v139_i9_sS_COVER.inddID_v139_i9_sS_COVER.indd 1 331-07-20191-07-2019 20:33:1120:33:11 JOURNAL OF INVESTIGATIVE DERMATOLOGY The official journal of The Society for Investigative Dermatology and European Society for Dermatological Research Volume 139 Number 9S, Supplement 2, September 2019 Editor Mark C. Udey, St. Louis, MO Principal Deputy Editor Medical Writer Thomas Krieg, Cologne, Germany Heather Yarnall Schultz, Huntington, WV Deputy Editors JID Connector Editor Leena Bruckner-Tuderman, Freiburg, Germany Lynn A. Cornelius, St. Louis, MO Kilian Eyerich, Munich, Germany David E. Fisher, Boston, MA Cells to Surgery Quiz Contributors Joel M. Gelfand, Philadelphia, PA Jeremy Etzkorn, Philadelphia, PA Valerie Horsley, New Haven, CT Eva Hurst, St. Louis, MO Sarah E. Millar, Philadelphia, PA Rajiv Nijhawan, Dallas, TX Tony Oro, Stanford, CA Keyvan Nouri, Miami, FL Vincent Piguet, Toronto, Canada Meet the Investigator Editor Section Editors Ayman Grada, Boston, MA Martine Bagot, Paris, France Meeting Reports Section Editor Isaac Brownell, Bethesda, MD Jouni Uitto, Philadelphia, PA An-Wen Chan, Toronto, Canada Keith A. Choate, New Haven, CT Podcast Editor Andrzej Dlugosz, Ann Arbor, MI Robert Dellavalle, Denver, CO James T. Elder, Ann Arbor, MI Research Techniques Made Simple Janet Fairley, Iowa City, IA Jodi Lynn Johnson, Chicago, IL, Coordinating Editor John E. Harris, Worcester, MA Sara J. Brown, Dundee, UK, Contributing Editor Daniel H. Kaplan, Pittsburgh, PA Lu Q. Le, Dallas, TX, Contributing Editor Ethan A. Lerner, Boston, MA Carien M. Niessen, Cologne, Germany SnapshotDx Quiz Contributors Martin Roecken, Tu¨bingen, Germany Milan Anadkat, St. Louis, MO Thomas Schwarz, Kiel, Germany Ben Chong, Dallas, TX Phyllis I. Spuls, Amsterdam, The Netherlands Emily Chu, Philadelphia, PA Marjana Tomic-Canic, Miami, FL Mariya Miteva, Miami, FL Miriam Wittmann, Leeds, UK Editors Emeriti Statistical Editor Marion B. Sulzberger, 1938-1949 Chao Xing, Dallas, TX Naomi M. Kanof, 1949-1967 Richard B. Stoughton, 1967-1972 Reviews Editors Irwin M. Freedberg, 1972-1977 Johann E. Gudjonsson, Ann Arbor, MI Ruth K. Freinkel, 1977-1982 David P. Kelsell, London, UK Howard P. Baden, 1982-1987 David A. Norris, 1987-1992 Managing Editor Edward J. O’Keefe, 1992-1997 Elizabeth Nelson Blalock, Chapel Hill, NC Conrad Hauser, 1997-2002 Lowell A. Goldsmith, 2002-2007 Editorial Process Manager Paul R. Bergstresser, 2007-2012 Sarah Forgeng, Chapel Hill, NC Barbara A. Gilchrest, 2012-2017 Editorial Consultants Masayuki Amagai, Tokyo, Japan Kathleen J. Green, Chicago, IL Fernanda Sakamoto, Boston, MA Maryam Asgari, Boston, MA Michael Hertl, Marburg, Germany Helmut Schaider, Brisbane, Australia Ju¨rgen Becker, Graz, Austria Alain Hovnanian, Paris, France Christoph Schlapbach, Berne, Switzerland Mark Berneburg, Tu¨bingen, Germany Sam Hwang, Sacramento, CA Martin Schmelz, Berne, Switzerland Tilo Biedermann, Munich, Germany Rivkah Isseroff, Davis, CA Vijayasaradhi Setaluri, Madison, WI Wendy B. Bollag, Augusta, GA Andrew Johnston, Ann Arbor, MI John Seykora, Philadelphia, PA Vladimir Botchkarev, Bradford, UK Kenji Kabashima, Kyoto, Japan Jan C. Simon, Leipzig, Germany Joke Bouwstra, Leiden, The Netherlands Veli-Matti Ka¨ha¨ri, Turku, Finland Eli Sprecher, Tel Aviv, Israel Paul E. Bowden, Cardiff, UK Tatsuyoshi Kawamura, Yamanashi, Japan Robert S. Stern, Boston, MA Julide Celebi, New York, NY Reinhard Kirnbauer, Vienna, Austria Georg Stingl, Vienna, Austria Angela M. Christiano, New York, NY Heidi H. Kong, Bethesda, MD Makoto Sugaya, Tokyo, Japan Cheng-Ming Chuong, Los Angeles, CA Jo Lambert, Ghent, Belgium Robert Swerlick, Atlanta, GA Cristina de Guzman Strong, St. Louis, MO Alexander G. Marneros, Boston, MA Sergey M. Troyanovsky, Chicago, IL Thomas N. Darling, Bethesda, MD Caterina Missero, Napoli, Italy Hensin Tsao, Boston, MA Jeffrey M. Davidson, Nashville, TN Maria Morasso, Bethesda, MD Erwin Tschachler, Vienna, Austria Robert Dellavalle, Denver, CO Akimichi Morita, Nagoya, Japan Jouni Uitto, Philadelphia, PA Mitchell F. Denning, Chicago, IL Keisuke Nagao, Bethesda, MD Maurice van Steensel, Dundee, UK Richard L. Eckert, Baltimore, MD Paul Nghiem, Seattle, WA Baoxi Wang, Beijing, China Tatiana Efimova, Washington, DC Tamar Nijsten, Rotterdam, The Netherlands Nicole L. Ward, Cleveland, OH Alexander H. Enk, Heidelberg, Germany Manabu Ohyama, Tokyo, Japan Wendy Weinberg, Bethesda, MD Gary J. Fisher, Ann Arbor, MI Amy S. Paller, Chicago, IL Thomas Werfel, Hannover, Germany Mayumi Fujita, Aurora, CO Andrey A. Panteleyev, Moscow, Russia Traci Wilgus, Columbus, OH Richard Gallo, San Diego, CA Carlo Pincelli, Modena, Italy Giovanna Zambruno, Rome, Italy Spiro Getsios, Collegeville, PA Grac¸a Raposo, Paris, France Xuejun Zhang, Heifei, China Michel F. Gilliet, Lausanne, Switzerland Dennis Roop, Denver, CO Bin Zheng, Charlestown, MA Matthias Goebeler, Wu¨rzburg, Germany Sarbjit S. Saini, Baltimore, MD Detlef Zillikens, Lu¨beck, Germany JOURNAL OF INVESTIGATIVE DERMATOLOGY www.jidonline.org Copyright ª 2019 Society for Investigative Dermatology, Inc. This site also provides detailed Information for Authors. Contact details for ISSN 0022-202X questions arising after acceptance of an article, especially those relating to SCOPE proofs, are provided after registration of an article for publication. The Journal of Investigative Dermatology is published monthly in print REPRINTS and online. The journal provides an international forum for the pub- For queries about author offprints, e-mail [email protected]. lication of high-quality, original articles. JID features information on all To order 100 or more reprints for educational, commercial, or promo- aspects of cutaneous biology and skin disease. tional use, contact Derrick Imasa at Elsevier Inc, 230 Park Avenue, Suite This journal is covered by Adonis, BIOSIS, CAB Abstracts, Chemical 800, New York, NY 10169; Tel: +1 215 633 3874; Fax: +1 212 462 1935; Abstracts Databases, CurrentContents/ClinicalMedicine, CurrentCon- E-mail: [email protected]. Reprints of single articles available online tents/Life Sciences, Derwent Journals Abstracted, EBSCO, Embase/ may be obtained by purchasing Pay-Per-View access for $31.50 per Excerpta Medica, Global Health, Index Medicus/MEDLINE, International article on the journal Web site, www.jidonline.org. Pharmaceutical Abstracts, PASCAL, Reference Update, Science Citation PERMISSIONS Index, SciSearch/SCI Expanded, Sociedad Iberoamericana de Informa- This journal and the individual contributions contained in it are pro- cion Cientifica (SIIC) Database. tected under copyright, and the following terms and conditions apply EDITORIAL to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual All correspondence should be addressed to: Elizabeth Blalock, Managing article: Editor for The Journal of Investigative Dermatology, P.O. Box 429, Photocopying: Single photocopies of single articles may be made for Chapel Hill, NC 27514. Tel: +1 919 932 0140. E-mail: JIDoffice@ personal use as allowed by national copyright laws. Permission is not sidnet.org. All manuscripts should be submitted online at: http://jid. required for photocopying of articles published under the CC BY license manuscriptcentral.com. nor for photocopying for non-commercial purposes in accordance with SOCIETY any other user license applied by the publisher. Permission of the pub- For information, contact the Society for Investigative Dermatology at lisher and payment of a fee is required for all other photocopying, [email protected] or the European Society for Dermatological Research at including multiple or systematic copying, copying for advertising or offi[email protected]. Detailed instructions to authors are available at the promotional purposes, resale, and all forms of document delivery. Spe- journal website, www.jidonline.org. cial rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. CUSTOMER SERVICE Derivative Works: Users may reproduce tables of contents or pre- Address orders, claims, change of address to: Elsevier Health Sciences pare lists of articles including abstracts for internal circulation within Division, Subscription Customer Service, 3251 Riverport Lane, Maryland their institutions or companies. Other than for articles published under Heights, MO 63043. Tel: +1 800 654 2452 (toll free US and Canada); the CC BY license, permission of the publisher is required for resale or +1 314 447 8871 (outside US and Canada). Fax: +1 314 447 8029. distribution outside the subscribing institution or company. For any E-mail: [email protected] (for print support); subscribed articles or articles published under a CC BY-NC-ND license, [email protected] (for online support). Address permission of the publisher is required for all other derivative works, changes must be submitted four weeks in advance. including compilations and translations. SUBSCRIPTIONS Storage or Usage: Except as outlined above or as set out in the Personal print & electronic subscriptions: $972 US, $1,247 Canada, relevant user license, no part of this publication may be reproduced, $1,199 Rest of World stored in a retrieval system or transmitted in any form or by any means, Personal electronic
Load more

Recommended publications
  • Stanford Chem-H Presentation (PDF)
    KiNativ® In situ kinase profiling Stanford University ChEM-H confidential @KiNativPlatform Principle of the KiNativ platform • ATP (or ADP) acyl phosphate binds to, and covalently modifies Lysine residues in the active site • Thus, ATP acyl phosphate with a desthiobiotin tag can be used capture and quantitate kinases in a complex lysate Acyl phosphate Desthiobiotin tag ATP 2 ATP acyl phosphate probe covalently modifies kinase in the active site Lysine 2 Lysine 1 3 ATP acyl phosphate probe covalently modifies kinase in the active site Lysine 2 Lysine 1 4 Samples trypsinized, probe-labeled peptides captured with streptavidin, and analyzed by targeted LC-MS2 Identification Quantitation Explicit determination of peptide Integration of signal from MS2 sequence and probe modification site fragment ions from MS2 spectrum 5 Comprehensive Coverage of Protein and Lipid Kinases Protein kinases Atypical kinases Green: Kinases detected on KiNativ Red: Kinases not detected on KiNativ ~80% of known protein and atypical kinases identified on the platform http://www.kinativ.com/coverage/protein-lipid.html 6 Profiling compound(s) on the KiNativ platform Control sample – add probe Sample: Lysate derived from any cell line or tissue from ANY species Treated sample – add inhibitor followed by probe Inhibited kinase Green: Kinases Blue: Probe Gray: Non-kinases Red: Inhibitor 7 Profiling compound(s) on the KiNativ platform Control sample – add probe MS signalMS Sample: Lysate derived from any cell line or tissue from ANY species Treated sample – add inhibitor
    [Show full text]
  • 3628-3641-Pruritus in Selected Dermatoses
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2016; 20: 3628-3641 Pruritus in selected dermatoses K. OLEK-HRAB 1, M. HRAB 2, J. SZYFTER-HARRIS 1, Z. ADAMSKI 1 1Department of Dermatology, University of Medical Sciences, Poznan, Poland 2Department of Urology, University of Medical Sciences, Poznan, Poland Abstract. – Pruritus is a natural defence mech - logical self-defence mechanism similar to other anism of the body and creates the scratch reflex skin sensations, such as touch, pain, vibration, as a defensive reaction to potentially dangerous cold or heat, enabling the protection of the skin environmental factors. Together with pain, pruritus from external factors. Pruritus is a frequent is a type of superficial sensory experience. Pruri - symptom associated with dermatoses and various tus is a symptom often experienced both in 1 healthy subjects and in those who have symptoms systemic diseases . Acute pruritus often develops of a disease. In dermatology, pruritus is a frequent simultaneously with urticarial symptoms or as an symptom associated with a number of dermatoses acute undesirable reaction to drugs. The treat - and is sometimes an auxiliary factor in the diag - ment of this form of pruritus is much easier. nostic process. Apart from histamine, the most The chronic pruritus that often develops in pa - popular pruritus mediators include tryptase, en - tients with cholestasis, kidney diseases or skin dothelins, substance P, bradykinin, prostaglandins diseases (e.g. atopic dermatitis) is often more dif - and acetylcholine. The group of atopic diseases is 2,3 characterized by the presence of very persistent ficult to treat . Persistent rubbing, scratching or pruritus.
    [Show full text]
  • Scabies in Healthcare Facilities
    Scabies in Healthcare Facilities Tammra L. Morrison, RN BSN Healthcare Associated Infections Coordinator Communicable Disease Branch, Epidemiology Section December 9, 2016 Symptoms • In a person who has never had scabies: • May take 4-6 weeks for symptom onset • In a person who has had scabies in the past: • Symptoms may start in 1-4 days • May be spread PRIOR to symptom onset What to Look for • Intense itching • Especially at night • Pimple-like itchy rash • May affect entire body OR Dermatologie.md common sites: • Wrist, elbow, armpit, webbing between the fingers, nipple, penis, waist, belt-line, and buttocks • Burrows (tunnels) may be seen on the skin • Tiny raised and crooked grayish-white or skin- colored lines Transmission • Direct, prolonged, skin-to-skin contact with an infested person • Sexual partners • Household members • Quick handshake/hug will usually not spread scabies How Long Do Mites Live? • 1-2 months on a person • 48-72 hours off a person • Scabies mites will die at 122 degrees for 10 minutes Webmd.com 5 Diagnosis • Customary appearance and distribution of the rash and presence of burrows. • Confirm diagnosis: • Obtain a skin scraping to examine under a microscope for mites, eggs, or mite fecal matter • Person can still be infested even if mites, eggs, or fecal matter cannot be found • Typically fewer than 10-15 mites present on the entire body • **Crusted scabies may be thousands of mites and should be considered highly contagious** How Do You Treat Scabies? 7 Treatment • Available only by prescription • No "over-the-counter“
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Drugs https://doi.org/10.1007/s40265-020-01261-8 CURRENT OPINION JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors Miguel Nogueira1 · Luis Puig2 · Tiago Torres1,3 © Springer Nature Switzerland AG 2020 Abstract Despite advances in the treatment of psoriasis, there is an unmet need for efective and safe oral treatments. The Janus Kinase– Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays a signifcant role in intracellular signalling of cytokines of numerous cellular processes, important in both normal and pathological states of immune-mediated infamma- tory diseases. Particularly in psoriasis, where the interleukin (IL)-23/IL-17 axis is currently considered the crucial pathogenic pathway, blocking the JAK–STAT pathway with small molecules would be expected to be clinically efective. However, relative non-specifcity and low therapeutic index of the available JAK inhibitors have delayed their integration into the therapeutic armamentarium of psoriasis. Current research appears to be focused on Tyrosine kinase 2 (TYK2), the frst described member of the JAK family. Data from the Phase II trial of BMS-986165—a selective TYK2 inhibitor—in psoriasis have been published and clinical results are encouraging, with a large Phase III programme ongoing. Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment. Results of studies with TYK2 inhibitors will be important in assessing the clinical efcacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis.
    [Show full text]
  • Extrafacial Granuloma Faciale
    Journal of the American Osteopathic College of Dermatology Volume 11, Number 1 SPONSORS: ',/"!,0!4(/,/'9,!"/2!4/29s-%$)#)3 July 2008 34)%&%,,!"/2!4/2)%3s'!,$%2-! www.aocd.org Journal of the American Osteopathic College of Dermatology Journal of the American Osteopathic College of Dermatology 2007-2008 Officers President: Jay Gottlieb, DO President Elect: Donald Tillman, DO First Vice President: Marc Epstein, DO Second Vice President: Leslie Kramer, DO Third Vice President: Bradley Glick, DO Secretary-Treasurer: Jere Mammino, DO (2007-2010) Immediate Past President: Bill Way, DO Trustees: James Towry, DO (2006-2008) Mark Kuriata, DO (2007-2010) Karen Neubauer, DO (2006-2008) David Grice, DO (2007-2010) Sponsors: Global Pathology Laboratory Editors Stiefel Laboratories Jay S. Gottlieb, D.O., F.O.C.O.O. Medicis Stanley E. Skopit, D.O., F.A.O.C.D. James Q. Del Rosso, D.O., F.A.O.C.D. Galderma Editorial Review Board Ronald Miller, D.O. JAOCD Eugene Conte, D.O. Founding Sponsor Evangelos Poulos, M.D. Stephen Purcell, D.O. Darrel Rigel, M.D. !/#$s%)LLINOISs+IRKSVILLE -/ s&!8 Robert Schwarze, D.O. WWWAOCDORG Andrew Hanly, M.D. #/092)'(4!.$0%2-)33)/.WRITTENPERMISSIONMUSTBEOBTAINED Michael Scott, D.O. FROMTHE*OURNALOFTHE!MERICAN/STEOPATHIC#OLLEGEOF$ERMATOLOGY FORCOPYINGORREPRINTINGTEXTOFMORETHANHALFPAGE TABLESORlGURES Cindy Hoffman, D.O. 0ERMISSIONSARENORMALLYGRANTEDCONTINGENTUPONSIMILARPERMISSION Charles Hughes, D.O. FROMTHEAUTHORS INCLUSIONOFACKNOWLEDGEMENTOFTHEORIGINALSOURCE ANDAPAYMENTOFPERPAGE TABLEORlGUREOFREPRODUCEDMATERIAL Bill Way, D.O. 0ERMISSIONFEESAREWAIVEDFORAUTHORSWISHINGTOREPRODUCETHEIROWN Daniel Hurd, D.O. ARTICLES2EQUESTFORPERMISSIONSHOULDBEDIRECTEDTO*!/#$CO!/#$ 0/"OX+IRKSVILLE -/ Mark Lebwohl, M.D. #OPYRIGHTBYTHE*OURNALOFTHE!MERICAN/STEOPATHIC#OLLEGEOF Edward Yob, D.O. $ERMATOLOGY Jere Mammino, D.O. Printed by: Stoyles Graphics Services, Mason City, IA 50401 Schield M.
    [Show full text]
  • CCA Senior Care Options Formulary
    Commonwealth Care Alliance Senior Care Option HMO SNP 2021 List of Covered Drugs Formulary 30 Winter Street • Boston, MA 02108 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN This formulary was updated on 08/01/2021. For more recent information or other questions, please contact Senior Care Options Program (HMO SNP) Member Services, at 1-866-610-2273 or, for TTY users, 711, 8 a.m. – 8 p.m., 7 days a week, or visit www.commonwealthcaresco.org. HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Senior Care Options Program (HMO SNP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DO CUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Commonwealth Care Alliance. When it refers to “plan” or “our plan,” it means 2021 Senior Care Options Program. This document includes list of the drugs (formulary) for our plan which is current as of 08/01/2021. This formulary document applies to all SCO members. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy n etwork, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.
    [Show full text]
  • Changes to the Highmark Drug Formularies
    AUGUST 2020 JULY/AUGUST 2020 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for July/August 2020. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in June 2020 by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Progressive Formulary and the Highmark Progressive Healthcare Reform Formulary C. Changes to the Highmark Healthcare Reform Essential Formulary D. Changes to the Highmark Core Formulary E. Changes to the Highmark National Select Formulary F. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs Section II. Highmark Medicare Part D Formularies A. Changes to the Highmark Medicare Part D 5-Tier Incentive Formulary B. Changes to the Highmark Medicare Part D 5-Tier Closed Formulary C. Additions to the Specialty Tier D. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Quantity Level Limit (QLL) Program As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left.
    [Show full text]
  • Stem Cell/Wnt
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Stem Cell/Wnt Stem cells are required for continuous tissue maintenance within diverse organs, stem cell activity is often externally dictated by the microenvironment (the niche) so that stem cell output is precisely shaped to meet homeostatic needs or regenerative demands. Several key signaling pathways have been shown to play essential roles in this regulatory capacity. Specifically, the JAK/STAT, Hedgehog, Wnt, Notch, Smad, PI3K/phosphatase and tensin homolog, and NK-κB signaling pathways have all been shown experimentally to mediate various stem cell properties, such as self-renewal, cell fate decisions, survival, proliferation, and differentiation. Recent studies mainly focus on cancer stem cell, induced pluripotent stem cell, neural stem cell and maintenance of embryonic stem cell pluripotency. Cancer stem cells (CSCs) have been believed to be responsible for tumor initiation, growth, and recurrence. Numerous agents have been developed to specifically target CSCs by suppressing the expression of pluripotency maintaining factors Nanog, Oct-4, Sox-2, and c-Myc and transcription of GLI. Induced pluripotent stem cells (iPSCs) have the capacity to differentiate into various types of cells, and a self-renewing resource, and scientists can experiment with an unlimited number of pluripotent cells to perfect the process of targeted differentiation, transplantation, and more, for personalized medicine. Novel pathological mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline and the first clinical trial using human iPSC-derived products has been initiated. References: [1] Clevers H, et al. Science. 2014 Oct 3;346(6205):1248012. [2] Matsui WH. Medicine (Baltimore).
    [Show full text]
  • Prospective Observational Study in a Tertiary
    CLINICAL STUDY OF PROFILE OF ADOLESCENT DERMATOSES AND THEIR EFFECT ON QUALITY OF LIFE IN ADOLESCENTS – PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA Dissertation Submitted to THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY IN PARTIAL FULFILMENT FOR THE AWARD OF THE DEGREE OF DOCTOR OF MEDICINE IN DERMATOLOGY, VENEREOLOGY & LEPROSY Register No.: 201730251 BRANCH XX MAY 2020 DEPARTMENT OF DERMATOLOGY VENEREOLOGY & LEPROSY TIRUNELVELI MEDICAL COLLEGE TIRUNELVELI -11 BONAFIDE CERTIFICATE This is to certify that this dissertation entitled “CLINICAL STUDY OF PROFILE OF ADOLESCENT DERMATOSES AND THEIR EFFECT ON QUALITY OF LIFE IN ADOLESCENTS – PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA” is a bonafide research work done by Dr.ARAVIND BASKAR.M, Postgraduate student of Department of Dermatology, Venereology and Leprosy, Tirunelveli Medical College during the academic year 2017 – 2020 for the award of degree of M.D. Dermatology, Venereology and Leprosy – Branch XX. This work has not previously formed the basis for the award of any Degree or Diploma. Dr.P.Nirmaladevi.M.D., Professor & Head of the Department Department of DVL Tirunelveli Medical College, Tirunelveli - 627011 Dr.S.M.Kannan M.S.Mch., The DEAN Tirunelveli Medical College, Tirunelveli - 627011 CERTIFICATE This is to certify that the dissertation titled as “CLINICAL STUDY OF PROFILE OF ADOLESCENT DERMATOSES AND THEIR EFFECT ON QUALITY OF LIFE IN ADOLESCENTS – PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA” submitted by Dr.ARAVIND BASKAR.M is a original work done by him in the Department of Dermatology,Venereology & Leprosy,Tirunelveli Medical College,Tirunelveli for the award of the Degree of DOCTOR OF MEDICINE in DERMATOLOGY, VENEREOLOGY AND LEPROSY during the academic period 2017 – 2020.
    [Show full text]
  • Salicylic Acid
    Treatment Guide to Common Skin Conditions Prepared by Loren Regier, BSP, BA, Sharon Downey -www.RxFiles.ca Revised: Jan 2004 Dermatitis, Atopic Dry Skin Psoriasis Step 1 - General Treatment Measures Step 1 - General Treatment Measures Step 1 • Avoid contact with irritants or trigger factors • Use cool air humidifiers • Non-pharmacologic measures (general health issues) • Avoid wool or nylon clothing. • Lower house temperature (minimize perspiration) • Moisturizers (will not clear skin, but will ↓ itching) • Wash clothing in soap vs detergent; double rinse/vinegar • Limit use of soap to axillae, feet, and groin • Avoid frequent or prolonged bathing; twice weekly • Topical Steroids Step 2 recommended but daily bathing permitted with • Coal Tar • Colloidal oatmeal bath products adequate skin hydration therapy (apply moisturizer • Anthralin • Lanolin-free water miscible bath oil immediately afterwards) • Vitamin D3 • Intensive skin hydration therapy • Limit use of soap to axillae, feet, and groin • Topical Retinoid Therapy • “Soapless” cleansers for sensitive skin • Apply lubricating emollients such as petrolatum to • Sunshine Step 3 damp skin (e.g. after bathing) • Oral antihistamines (1st generation)for sedation & relief of • Salicylic acid itching give at bedtime +/- a daytime regimen as required Step 2 • Bath additives (tar solns, oils, oatmeal, Epsom salts) • Topical hydrocortisone (0.5%) for inflammation • Colloidal oatmeal bath products Step 2 apply od-tid; ointments more effective than creams • Water miscible bath oil • Phototherapy (UVB) may use cream during day & ointment at night • Humectants: urea, lactic acid, phospholipid • Photochemotherapy (Psoralen + UVA) Step 4 Step 3 • Combination Therapies (from Step 1 & 2 treatments) • Prescription topical corticosteroids: use lowest potency • Oral antihistamines for sedation & relief of itching steroid that is effective and wean to twice weekly.
    [Show full text]
  • Dermatological Effects of Different Keratolytic Agents on Acne Vulgaris
    Clin l of ica a l T n r r i u a l o s J Alodeani, J Clin Trials 2016, 6:2 Journal of Clinical Trials DOI: 10.4172/2167-0870.1000262 ISSN: 2167-0870 Research Article Open Access Dermatological Effects of Different Keratolytic Agents on Acne Vulgaris Essa Ajmi Alodeani* College of Medicine at AD-Dwadmi, Shaqra University, Saudi Arabia *Corresponding author: Essa Ajmi Alodeani, College of Medicine at AD-Dwadmi, Shaqra University, Saudi Arabia, Tel: +966 55 075 9042; E-mail: [email protected] Received date: March 24, 2016; Accepted date: April 18, 2016; Published date: April 25, 2016 Copyright: © 2016 Alodeani EA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Acne vulgaris is a chronic inflammatory skin disease; it's one of the most common skin disorders and affects mainly adolescents and young adults. Keratolytic agents are widely used in treatment of acne from several years. In this study we aimed to evaluate and compare the cutaneous response of different keratolytic agents in management of acne vulgaris. Ninety patients were selected among those attending the outpatient dermatology clinic in AD- Dwadmi hospital during the period from October 2015 to February 2016. The selected patients had different forms of acne vulgaris, papulo-pustular, comedonal and post acne scar. Three types of keratolytic agents were used, glycolic acid 50%, salicylic acid 20% and jessner solution. In papulopustular lesions, the three agents were effective with non-significant difference between them; however, there was more excellent results with jessner solution (70 % of patients) then glycolic acid (50%) and lastly salicylic acid (40%).
    [Show full text]